Clinical Trials Logo

Clinical Trial Summary

The purpose of this research is to examine whether the Chronic Disease Self-management Program (CDSMP) would improve health outcomes and reduce health care use in African American women with systemic lupus erythematosus (SLE). The CDSMP is a generic, evidence-based self-management education program that has been shown to help people with chronic conditions to take control of their health problems. This study focuses on African American women with SLE because the CDSMP has not been widely studied in this population.


Clinical Trial Description

The CDSMP is an evidence-based, community-based, generic self-management program that consists of 6 weekly classes of two and a half hours each one, for six weeks. CDSMP classes are facilitated by certified peer leaders. Because the CDSMP is widely disseminated and available to the adult U.S. population through community centers, it may be a suitable and accessible option for African Americans with SLE, even though it is not specifically tailored to SLE or to African Americans. As the CDSMP has been primarily evaluated in predominantly white middle-class seniors with more common diseases (e.g. osteoarthritis, diabetes), the effectiveness of the CDSMP in helping African American women to self-manage SLE is unknown. This study will examine the effectiveness of the CDSMP to improve patient-reported outcomes and reduce health care utilization in African American women with lupus. Using a two-group longitudinal cohort design with participants sampled from a parent population-based SLE cohort in Georgia, investigators will examine behaviors, health and healthcare outcomes, and the extent to which individual characteristics modify the effectiveness of the CDSMP. The Georgians Organized Against Lupus (GOAL), a longitudinal cohort of patients with a validated diagnosis of SLE, will be used to enroll participants into the intervention. A random sample of African American women with SLE selected from the parent GOAL cohort will be recruited into the WELL (Women Empowered to Live with Lupus) cohort. WELL participants will attend the CDSMP classes in the community, along with people with other chronic illnesses. WELL participants will be asked to attend the CDSMP in the community and answer questionnaires at 4 select time periods before and after the program. Investigators will follow participant's progress for up to 18 months after they attend the CDSMP. African American women from the GOAL cohort non-selected to be assigned to the intervention will comprise the usual care group. Participants will continue their longitudinal assessments as part of the GOAL cohort data collection efforts. Changes in outcomes for up to 18 months will be compared between WELL participants and the usual care group. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02988661
Study type Interventional
Source Emory University
Contact
Status Active, not recruiting
Phase N/A
Start date January 19, 2017
Completion date February 2025

See also
  Status Clinical Trial Phase
Completed NCT03248518 - Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases N/A
Recruiting NCT05967520 - JMKX000189 for Moderate to Severe Active Systemic Lupus Erythematosus Phase 2
Completed NCT02875691 - Effect of Green Tea on Treatment of Lupus Phase 2
Completed NCT02922114 - Comparison of the Clinical Examination and the Joint Ultrasonography in Lupus Patients N/A
Withdrawn NCT01702038 - Determining the Responses and Impact of Rituximab-instigated Cell Depletion on T Cells in People With SLE Phase 2
Terminated NCT00368264 - TNF Blockade With Remicade in Active Lupus Nephritis WHO Class V (TRIAL ) Phase 2/Phase 3
Completed NCT00094380 - Treating Systemic Lupus Erythematosus (SLE) Patients With CTLA4-IgG4m (RG2077) Phase 1/Phase 2
Completed NCT00065806 - Atherosclerosis Prevention in Pediatric Lupus Erythematosus (APPLE) Phase 3
Completed NCT00005436 - Lupus Cohort--Thrombotic Events and Coronary Artery Disease N/A
Recruiting NCT03543839 - Trial of Belimumab in Early Lupus Phase 4
Completed NCT03098823 - A Crossover Study to Compare RAYOS to IR Prednisone to Improve Fatigue and Morning Symptoms for SLE Phase 4
Recruiting NCT05899907 - Efficacy and Safety of Telitacicept in Early SLE Phase 4
Completed NCT04956484 - Belimumab In Early Systemic Lupus Erythematosus Phase 4
Completed NCT05326841 - Effect of Cholecalciferol Supplementation on Disease Activity and Quality of Life of Systemic Lupus Erythematosus Patients . Phase 3
Completed NCT02655640 - The Impact of Illness Perceptions on Health Related Outcomes in Patients With Lupus and Systemic Sclerosis N/A
Completed NCT02034344 - A Study of Skin and Systemic Biomarkers In Patients With Active Cutaneous Lupus Erythematosus And In Healthy Volunteers Phase 0
Terminated NCT00089804 - Study of LJP 394 in Lupus Patients With History of Renal Disease Phase 3
Completed NCT00071487 - Safety and Efficacy Study of LymphoStat-B (Belimumab) in Subjects With Systemic Lupus Erythematosus (SLE) Phase 2
Completed NCT02349061 - A Phase 2a, Efficacy and Safety Study of Ustekinumab in Systemic Lupus Erythematosus Phase 2
Recruiting NCT05636670 - Assessment of Cognitive Function and Gut Microbiota Analysis in Real World Patients With Lupus Cerebrovascular Disease